Role of protein kinase C inhibition in the development of diabetic microvascular complications

References

• Wild S, Roglic G, Green A et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care21, 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• Hedley AA, Ogden CL, Johnson CL et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA291, 2847–2850 (2004).
   PubMed Web of Science ®Google Scholar
• Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clin. Invest. Med.18, 231–239 (1995).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Self-rated fair or poor health among adults with diabetes – United States,1996–2005. MMWR Morb. Mortal. Wkly Rep.55(45), 1224–1227 (2006).
   PubMedGoogle Scholar
• Morgan CL, Currie CJ, Stott NC et al. The prevalence of multiple diabetes-related complications. Diabet. Med.17, 146–151 (2000).
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA287, 2570–2581 (2002).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Milicevic Z. Preventive measures and treatment options for diabetic neuropathy. Contemp. Intern. Med.6(10), 41–42, 47–55 (1994).
   Google Scholar
• Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology43(4), 817–824 (1993).
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in Type 2 diabetes mellitus. Arch. Intern. Med.159(16), 1873–1880 (1999).
   PubMed Web of Science ®Google Scholar
• Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type 2 diabetes. Diabetologia352, 837–853 (2002).
   Google Scholar
• Klein R, Klein BE, Moss SE. The Wisconsin Epidemiological Study of Diabetic Retinopathy: a review. Diabetes Metab. Rev.5, 559–570 (2002).
   Google Scholar
• Kempen JH, O’Colmain BJ, Leske MC et al. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol.122, 552–563 (2004).
   PubMed Web of Science ®Google Scholar
• Blindness caused by diabetes: Massachusetts, 1987–1994. MMWR Morb. Mortal. Wkly Rep.45, 937–941 (1996).
   PubMedGoogle Scholar
• Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care1, 168–188 (1978).
   Google Scholar
• Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia43, 957–973 (2000).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care26(Suppl. 1), S33–S50 (2003).
   PubMed Web of Science ®Google Scholar
• US Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2002).
   Google Scholar
• Girach A, Vignati L. Diabetic microvascular complications–can the presence of one predict the development of another? J. Diabetes Complications20(4), 228–237 (2006).
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann. Int. Med.122, 561–568 (1995).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetalogia41, 416–423 (1998).
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa J, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complication in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract.28, 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Vaag AA. Glycemic control and prevention of microvascular and microvascular disease in the Steno 2 Study. Endocrine Practice12(S1), 89–92 (2006).
   PubMedGoogle Scholar
• Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ III, O’Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care22(9), 1479–1486 (1999).
   PubMed Web of Science ®Google Scholar
• Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA88(20), 2579–2588 (2002).
   Google Scholar
• Hotta N, Toyota T, Matsuoka K et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. The SNK-860 Diabetic Neuropathy Study Group. Diabetes Care24, 1776–1782 (2001).
   PubMed Web of Science ®Google Scholar
• King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol. Pathol.54, 400–408 (2001).
   Google Scholar
• Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol.50, 325–392 (2002).
   PubMed Web of Science ®Google Scholar
• Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thiotic acid (α-lipoic acid): a two year multicentre randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic. Res.31, 171–179 (1999).
   PubMed Web of Science ®Google Scholar
• Anand P, Terenghi G, Warner G et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat. Med.2, 703–707 (1996).
   PubMed Web of Science ®Google Scholar
• Lee TS, Saltsman KA, Ohashi H, King GL. Activation of PKC by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc. Natl Acad. Sci. USA86, 5141–5145 (1989).
   PubMed Web of Science ®Google Scholar
• Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm.60, 149–193 (2000).
   PubMed Web of Science ®Google Scholar
• Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Comm.228, 539–543 (1996).
   PubMed Web of Science ®Google Scholar
• Walaas SI, Greengard P. Protein phosphorylation and neuronal function. Pharmacol. Rev.43, 299–349 (1991).
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science258, 607–614 (1992).
   PubMed Web of Science ®Google Scholar
• King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North Am.25(2), 255–270 (1996).
   PubMed Web of Science ®Google Scholar
• Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem. J.332, 281–292 (1998).
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev.101(8), 2353–2364 (2001).
   PubMed Web of Science ®Google Scholar
• Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem.6(9), 877–903 (1999).
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney. Int. Suppl.77, S26–S30 (2000).
   PubMed Web of Science ®Google Scholar
• Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene20(44), 6339–6347 (2001).
   PubMed Web of Science ®Google Scholar
• Sipeki S, Bander E, Farkas G, Gujdar A, Ways DK, Farago A. Protein kinase C decreases the hepatocyte growth factor-induced activation of Erk1/Erk2 MAP kinases. Cell Signal.12(8), 549–555 (2000).
   Google Scholar
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med.331, 1480–1487 (1994).
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform β2 and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl Acad. Sci. USA89, 11059–11063 (1992).
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science272, 728–731 (1996).
   PubMed Web of Science ®Google Scholar
• Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J. Clin. Invest.83, 1667–1675 (1989).
   PubMed Web of Science ®Google Scholar
• Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol.261, F571–F577 (1991).
   Google Scholar
• Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol.265, E783–E793 (1993).
   PubMed Web of Science ®Google Scholar
• Congdon N, O’Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol.122, 477–485 (2004).
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology105, 998–1003 (1998).
   PubMed Web of Science ®Google Scholar
• Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care27(S1), S84–S87 (2004).
   PubMed Web of Science ®Google Scholar
• Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Lewison SW. Diabetic retinopathy: more than meets the eye. Surv. Ophtalmol.47(Suppl. 2), S253–S262 (2004).
   Google Scholar
• Comer GM, Ciulla TA. Current and future pharmacological intervention for diabetic retinopathy. Expert Opin. Emerg. Drugs10(2), 441–455 (2005).
   PubMedGoogle Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care26(9), 2653–2664 (2003).
   PubMed Web of Science ®Google Scholar
• Xia P, Inoguchi T, Kern T, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes43, 1122–1129 (1994).
   PubMed Web of Science ®Google Scholar
• Wetsel WC, Khan WA, Merchenthaler I et al. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J. Cell Biol.117, 121–133 (1992).
   PubMed Web of Science ®Google Scholar
• Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes46, 1497–1503 (1997).
   PubMed Web of Science ®Google Scholar
• Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.38, 2729–2741 (1997).
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol.114, 66–71 (1996).
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Jirousek MR, Stramm L, Farid N, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes47, 464–469 (1998).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes46, 1473–1480 (1997).
   PubMed Web of Science ®Google Scholar
• Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC-β inhibition with LY333531. Invest. Ophthalmol. Vis. Sci.39, 171–179 (1998).
   PubMed Web of Science ®Google Scholar
• McGill JB, King GL, Berg PH et al. Clinical safety of the selective PKC-β inhibitor, ruboxistaurin. Expert Opin. Drug Saf.5(6), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci.47(1), 86–92 (2006).
   PubMed Web of Science ®Google Scholar
• PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy. Diabetes54, 2188–2197 (2005).
   PubMed Web of Science ®Google Scholar
• PKC DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• The PKC-DMES Study Group. Effect of ruboxistaurin, a PKC isoform-selective inhibitor, in patients with diabetic macular edema: 30-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. (2007) (In Press).
   Google Scholar
• Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab. Res. Rev.19(Suppl. 1), S16–S21 (2003).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Mehrabyan A. Diagnosis and management of diabetic autonomic neuropathy. Compr. Ther.29(2–3), 130–145 (2003).
   PubMedGoogle Scholar
• Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care27(6), 1458–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes, Neurodiab. Diabetes Metab.24(Suppl. 3), 55–65 (1998).
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy – a continuing enigma. Diabetes Metab. Res. Rev.16(6), 408–433 (2000).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Giannini C. Pathological alterations in the diabetic neuropathies of humans: a review. Neuropathol. Exp. Neurol.55(12), 1181–1193 (1996).
   PubMed Web of Science ®Google Scholar
• Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia44(11), 1973–1988 (2001).
   PubMed Web of Science ®Google Scholar
• Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am. J. Physiol.261(24), El–E8 (1991).
   Google Scholar
• Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C β inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clinical Science103, 311–321 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura J, Kato K, Hamada Y et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes48, 2090–2095 (1999).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Bril V, Kempler P et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double blind clinical trial. Clin. Ther.27, 1164–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Tandan R, Skljarevski V, Price KL, Kles KA, Bastyr EJ; for the Ruboxistaurin Treatment of DPN Study Group. Neuropathy Progression in Patients with Symptomatic Diabetic Peripheral Neuropathy: Experience from Phase 3 Ruboxistaurin Clinical Trials. Neurology66(5) (Suppl. 2), A191 (2006).
   Google Scholar
• Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C-β inhibition. Am. J. Kidney Dis.42(3), 456–465 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care28(S1), S4–S36 (2005).
   PubMed Web of Science ®Google Scholar
• Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: an update. Adv. Chronic Kidney Dis.12(2), 212–222 (2005).
   PubMed Web of Science ®Google Scholar
• Williams B, Schrier RW. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J. Clin. Invest.92(6), 2889–2896 (1993).
   PubMedGoogle Scholar
• Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J. Clin. Invest.93(1), 311–320 (1994).
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator. Diabetes44, 1139–1146 (1995).
   PubMed Web of Science ®Google Scholar
• Koya D, Haneda M, Nakagawa H et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for Type 2 diabetes. FASEB J.14, 439–447 (2000).
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in Type 2 diabetes. Diabetes Care28, 2686–2690 (2005).
   PubMed Web of Science ®Google Scholar